Apnimed, Inc. (APMD) Income Statement
APMD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAPMD revenue and net income
Where APMD's revenue goes
2025Each bar shows an amount and its share of revenue. APMD kept −2.4% of revenue as net income.
APMD profit margins
APMD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +380.1% | — | — | — |
| Gross profit | +584.3% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
APMD quarterly EPS vs estimates
Apnimed beat the analyst EPS estimate in 1 of the last 1 quarters. Next report: December 8, 2026.
APMD income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $38.5M | $8.0M |
| Cost of revenue | $6.7M | $3.4M |
| Gross profit | $31.8M | $4.6M |
| Research & development | $62.1M | $97.4M |
| Sales, general & admin | $23.5M | $21.5M |
| Total operating expenses | $92.3M | $122.2M |
| Operating income | −$53.8M | −$114.2M |
| Interest income | $1.4M | $5.7M |
| Income before taxes | −$932,000 | −$108.5M |
| Net income | −$932,000 | −$111.3M |
| EBITDA | −$53.8M | −$114.2M |
| Gross margin | 82.6% | 58.0% |
| Operating margin | −139.9% | −1,425.8% |
| Net margin | −2.4% | −1,389.2% |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $12.1M | $84.8M | $17.1M | $3.1M |
| Cost of revenue | $1.2M | $2.2M | $1.7M | $1.3M |
| Gross profit | $10.9M | $82.7M | $15.4M | $1.8M |
| Research & development | $9.9M | $8.1M | $16.0M | $23.5M |
| Sales, general & admin | $12.7M | $6.5M | $5.4M | $5.5M |
| Total operating expenses | $23.8M | $16.8M | $23.0M | $30.2M |
| Operating income | −$11.7M | $68.0M | −$5.9M | −$27.1M |
| Interest income | $970,000 | $218,000 | $309,000 | $431,000 |
| Income before taxes | $126.1M | $70.4M | −$5.6M | −$26.7M |
| Net income | $125.9M | $70.4M | −$69.5M | −$28.6M |
| EBITDA | −$11.7M | $68.0M | −$5.9M | −$27.1M |
| EPS (diluted) | $0.51 | — | — | — |
| Gross margin | 90.0% | 97.5% | 89.9% | 57.9% |
| Operating margin | −96.9% | 80.2% | −34.7% | −865.9% |
| Net margin | 1,042.5% | 83.0% | −406.0% | −914.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in APMD's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
APMD financial results
In fiscal year 2025 (ended December 31, 2025), Apnimed reported revenue of $38.5 million, up 380.1% from the year before. It had a net loss of $0.9 million, a net profit margin of −2.4%.
See the APMD stock overview for the latest quote and news, or the APMD chart for price history and technical indicators.
APMD income statement FAQ
What is Apnimed's annual revenue?
Apnimed reported total revenue of $38.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 380.1% from $8.0 million the previous year.
Is Apnimed profitable?
No. Apnimed reported a net loss of $0.9 million in fiscal 2025, a net profit margin of −2.4%; its operating margin was −139.9%.
What is Apnimed's gross margin?
Apnimed's gross margin was 82.6% in fiscal 2025: for every $100 of revenue, Apnimed kept $83 after the direct cost of its products and services.
How much does Apnimed spend on research and development?
Apnimed spent $62.1 million on research and development in fiscal 2025, 161.4% of revenue.
When will Apnimed report its next earnings?
Apnimed is expected to report results for the quarter ending September 30, 2026 on December 8, 2026.
When does Apnimed's fiscal year end?
Apnimed's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025.